Pediatric Drugs Market To Reach $232 Billion by 2035

Pediatric drugs market is projected to grow from $120 billion in 2025 to $232 billion by 2035, expanding at a CAGR of 6.8% during the forecast period (2026–2035). The market growth is strongly driven by the rising burden of pediatric diseases globally, increasing regulatory support for pediatric drug development, and advancements in biologics and targeted therapies. A key macro driver influencing the market is the growing pediatric population and disease prevalence. According to the World Health Organization (WHO), children under 18 years account for nearly 30% of the global population, with infectious diseases such as pneumonia and diarrhea remaining leading causes of mortality in children under five. Additionally, UNICEF reports over 5 million deaths annually in children under 5, largely from preventable conditions treatable through proper medication. This creates a substantial demand for pediatric-specific drug formulations. Furthermore, the U.S. Food and Drug Administration (FDA) highlights that over 75% of approved drugs lack adequate pediatric labeling, accelerating investments in pediatric clinical trials and formulation innovation. This growing gap between adult and pediatric therapeutics is directly translating into increased pharmaceutical R&D spending and commercialization of pediatric drugs.

Browse the full report description of “Pediatric Drug Market Size, Share & Trends Analysis Report, By Therapeutic Area - Infectious Diseases, Respiratory Disorders, Neurological Disorders, Oncology, By Drug Type - Branded & Generic, By Route of Administration - Oral, Parenteral, Inhalation, Topical, By End User - Hospitals, Pediatric Clinics, Homecare Settings, Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/pediatric-drugs-market-overview

Among product categories, biological fungicides (analogous to pediatric biologics in pharmaceuticals) represent the fastest-growing segment, driven by increasing adoption of targeted therapies, monoclonal antibodies, and gene-based treatments in pediatric care. These therapies are gaining traction due to their higher efficacy, reduced side effects, and precision targeting, particularly in pediatric oncology, autoimmune diseases, and rare genetic disorders.

Key market players are actively adopting strategic initiatives to strengthen their pediatric drug portfolios. In 2023, Pfizer Inc. expanded its pediatric vaccine portfolio through advancements in mRNA-based platforms targeting infectious diseases. In 2024, Novartis AG received regulatory approval expansion for Zolgensma, a gene therapy used in pediatric spinal muscular atrophy, reinforcing its leadership in rare pediatric diseases. Sanofi, in 2022, strengthened its immunology pipeline with pediatric indications for Dupixent through global clinical trial expansion. Meanwhile, Roche (Genentech) in 2023 expanded Hemlibra’s pediatric use cases, targeting hemophilia in children. GSK, in 2024, increased production capacity for pediatric vaccines, responding to rising global immunization demand. Additionally, Johnson & Johnson (Janssen) entered strategic collaborations in 2025 to accelerate pediatric oncology drug development, focusing on targeted immunotherapies. These developments highlight a strong shift toward innovation-driven growth, regulatory expansion, and global access strategies.

Recent Developments

• On April 23, 2024, the U.S. Food and Drug Administration granted accelerated approval to Tovorafenib (Ojemda) by Day One Biopharmaceuticals for pediatric low-grade glioma (LGG) with BRAF alterations, marking the first targeted systemic therapy for this segment, with a 51% response rate in trials.
• On November 15, 2024, the U.S. Food and Drug Administration approved Revumenib (Revuforj) by Syndax Pharmaceuticals for relapsed or refractory acute leukemia with KMT2A translocation in adult and pediatric patients (?1 year), marking a key advancement in targeted pediatric oncology therapies, with a 21.2% CR+CRh response rate in clinical trials.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Therapeutic Area
  • By Drug Type
  • By Route Administration
  • By End users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Abbvie, Amgen, Astrazeneca, Aurobindo pharma, Bayer, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pediatric Drug Market Report Segment

By Therapeutic Area

• Infectious Diseases
• Respiratory Disorders
• Neurological Disorders
• Oncology
• Gastrointestinal Disorders
• Cardiovascular Disorders
• Endocrine & Metabolic Disorders
• Immunological & Autoimmune Diseases
• Dermatological Disorders
• Others

 By Drug Type

• Branded (Patented) Drugs
• Generic Drugs

 By Route of Administration

• Oral
• Parenteral
• Inhalation
• Topical
• Others

 By End User

• Hospitals
• Pediatric Clinics
• Homecare Settings

Global Pediatric Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pediatric-drugs-market-overview